Our signal-regulatory protein alpha (SIRPα) antagonist is a monoclonal antibody that blocks the interaction between SIRPα and cluster of differentiation 47 (CD47). By blocking this interaction, the antagonist restores the immune functions of myeloid cells in the tumour microenvironment. This SIRPα antagonist is currently undergoing clinical investigation as a monotherapy and in combination with an immune checkpoint inhibitor in patients with advanced solid tumours.
BI 765063 is an investigational compound and has not been approved. Its safety and efficacy has not been established.
To find out more about ongoing clinical trials in cancer please go to: www.mystudywin...
Click on the red button above to subscribe to our RU-vid channel.
Taking cancer on through the power of the body’s immune system offers exciting potential. We are driven to develop first-in-class immuno-oncology treatments with breakthrough potential. Our focus, passion and commitment, combined with our strong collaborations, will help us transform expectations, give hope to more patients and help win the fight against cancer.
12 окт 2020
